Dr. Hsiao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
400 Parnassus Ave.
5th Floor, A550, UCSF Box 1222
San Francisco, CA 94143Phone+1 415-353-2350- Is this information wrong?
Education & Training
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2009
- Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
- Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
- CA State Medical License 2003 - 2025
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Start of enrollment: 2014 Jul 14
Publications & Presentations
PubMed
- Wnt pathway inhibition with the porcupine inhibitor LGK974 decreases trabecular bone but not fibrosis in a murine model with fibrotic bone.Hsuan Lung, Tania Moody, Ariane Zamarioli, Apsara Ram, Gauri Ganesh, Misun Kang, Sunita Ho, Kelly L Wentworth, Edward C Hsiao> ;JBMR Plus. 2024 May 1
- Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.Anastasia Diolintzi, Mst Shaela Pervin, Edward C Hsiao> ;Biomolecules. 2024 Mar 16
- Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification.Conan Juan, Alec C Bancroft, Ji Hae Choi, Johanna H Nunez, Chase A Pagani, Yen-Sheng Lin, Benjamin Levi, Edward C Hsiao> ;Biomolecules. 2024 Mar 14
- Join now to see all
Press Mentions
- Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaDecember 12th, 2017
- Organovo and UCSF Partner to Create 3D Bioprinted Tissues for Skeletal Disease ResearchJune 14th, 2016
- Developing the First Drug for a Deadly Bone DiseaseOctober 3rd, 2023
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- San Francisco VA Medical CenterSan Francisco, California
- UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: